Mode
Text Size
Log in / Sign up
Phase 4 N=46 Randomized Double-blind Treatment

Lumbar Plexus vs Quadratus Lumborum Block in Post-operative Pain Following Total Hip Replacement

Hip Osteoarthritis

Enrolled (actual)
46
Serious AEs
0.0%
Results posted
Jul 2021
Primary outcome: Primary: Pain at Rest After Surgery — 3.4; 3.6 score on a scale — p=.770

Study Design & Population

Study type
Interventional
Phase
Phase 4
Interventions
Lumbar plexus block (Procedure); Quadratus lumborum type 3 block (Procedure); Ropivacaine injection (Drug)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Sharad Khetarpal
Primary completion
May 2020

Outcome Measures

OutcomeResultp-value
PRIMARY
Pain at Rest After Surgery
2.8; 1.8 .122
PRIMARY
Pain With Movement After Surgery
4.9; 4.3 .379
PRIMARY
Pain at Rest After Surgery
2.8; 1.8 .122
PRIMARY
Pain With Movement After Surgery
4.9; 4.3 .379
PRIMARY
Pain at Rest After Surgery
2.8; 1.8 .122
PRIMARY
Pain With Movement After Surgery
4.9; 4.3 .379
SECONDARY
Pain During Physical Therapy
4.3; 4.2 .881
SECONDARY
Total Opioid Consumption During 24 Hours After Surgery
14.0; 14.7 .818
SECONDARY
Postoperative Time to Accomplish Walking 100 Feet
1449.1; 1358.3 .678
SECONDARY
Block Procedure Duration
11.7; 6.6 .002 sig
SECONDARY
Patients With Postoperative Quadriceps Weakness
15; 6 .007 sig
SECONDARY
Total Acetaminophen Consumption During 24 Hours After Surgery
2782.6; 3087.0 .271
SECONDARY
Total Celecoxib Consumption During 24 Hours After Surgery
191.3; 178.3 .810
SECONDARY
Total Ketorolac Consumption During 24 Hours After Surgery
9.8; 12.4 .676
SECONDARY
Total Gabapentin Consumption During 24 Hours After Surgery
382.6; 395.7 .908
SECONDARY
Total Oral Ketamine Consumption During 24 Hours After Surgery
7.4; 13.5 .270
SECONDARY
Opioid Consumption During 0-6 Hours After Surgery
3.4; 6.3 .015 sig
SECONDARY
Opioid Consumption During 6-12 Hours After Surgery
5.0; 3.4 .203
SECONDARY
Opioid Consumption During 12-24 Hours After Surgery
5.7; 5.0 .672

Summary

The Lumbar Plexus (LP) block is currently used as the standard-of-care regional anesthesia technique to provide postoperative pain management after primary hip replacement surgery at UPMC Shadyside Hospital. However, the LP technique is complex and can be associated with potentially serious side effects, including nerve injury, major bleeding, retroperitoneal hematoma, and intrathecal injection of local anesthetic. In rare instances the LP block can also lead to motor blockade, interfering with early ambulation. There are several case reports of Quadratus Lumborum inter-fascial block (QL3) giving equally adequate pain relief after total hip replacement surgery, and this QL3 block is performed routinely at this institution. The benefits to inter-fascial administration of local anesthetic include the avoidance of theoretical nerve injury, bleeding and intrathecal anesthetic administration associated with the direct interaction between the nerve and the nerve block needle. The purpose of this study is to show that QL3 block is non-inferior to the standard-of-care lumbar plexus block and should be used more regularly in hip replacement surgery. The study will be conducted as a prospective, randomized (1:1), double-blind, non-inferiority, active-comparator trial. The investigators plan to enroll 40 subjects, 20 in each treatment group. This study will prospectively investigate the efficacy of QL3 versus Classic LP block for post-operative pain management in subjects undergoing primary, unilateral hip replacement surgery and prospectively compare QL3 versus Classic LP block in time to mobilization and physical therapy response. Primary outcome measures include pain at rest and with movement at 6, 12 and 24 hours after surgery. Secondary outcomes will be time for first request for pain medication, total pain medications (narcotics and non-narcotic analgesics) given in 24 hours and the time of participant's ability to walk 100 feet as recorded by a physical therapist.

Eligibility Criteria

Inclusion Criteria

  • Patients 18-90 years old
  • Primary unilateral total hip arthroplasty
  • BMI 20 - 36
  • Male and Female
  • All races

Exclusion Criteria

  • Patient refusal
  • ASA class > or = 4
  • Pregnancy
  • Any condition precluding patient going home with in 24 hours of surgery
  • Non-English speaking or inability to participate in the study
  • Patients with coagulopathy or on therapeutic anticoagulation
  • Chronic Steroid Use
  • Narcotic Addiction
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03801265). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search